Difference between revisions of "Team:AQA Unesp"

Line 22: Line 22:
 
document.getElementById("text").innerHTML="In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!  
 
document.getElementById("text").innerHTML="In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!  
 
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
 
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
−
<b>Mouse over the image to learn more!</b>
+
<b>Mouse over the image to learn more!</b>";
−
";
+
 
}
 
}
 
</script>
 
</script>
Line 73: Line 72:
 
<br>
 
<br>
 
<p id="text">
 
<p id="text">
−
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sed pellentesque leo, at auctor neque. Maecenas rutrum justo vel tempor dictum. Duis lacus purus, tempor at turpis quis, hendrerit viverra lorem. Aliquam mattis venenatis est, vel porttitor quam feugiat at. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Curabitur quis ex consectetur tortor dictum hendrerit at quis orci. Vestibulum feugiat, odio nec gravida fermentum, urna felis rhoncus lorem, in viverra nibh ligula mollis ante. Suspendisse vel magna quis libero mattis dapibus sed dictum dolor. Curabitur sodales scelerisque metus efficitur fringilla. In id sollicitudin ante, ac volutpat nulla. Etiam at turpis dui. Praesent mi magna, ultricies quis fermentum vitae, malesuada sed augue.
+
In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!
 +
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
 +
<b>Mouse over the image to learn more!</b>
 
</p>
 
</p>
 
</div>
 
</div>

Revision as of 02:41, 30 June 2017



iGEM AQA_Unesp
.

Team: AQA_Unesp

Treating diabetes with probiotics


In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day! Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA. Mouse over the image to learn more!

Team: AQA_Unesp